durable responses to ibrutinib and venetoclax in r/r mcl: 3-year aim update
Published 4 years ago • 77 plays • Length 3:06Download video MP4
Download video MP3
Similar videos
-
3:37
sympatico: ibrutinib combined with venetoclax in patients with r/r mcl
-
3:18
sympatico: safety and efficacy of ibrutinib plus venetoclax for r/r mcl
-
3:28
the sympatico trial: ibrutinib plus venetoclax in tp53-mutated mcl
-
1:52
evaluating the efficacy of obinutuzumab, ibrutinib, and venetoclax in richter's transformation
-
2:23
zilo-301: phase iii study of zilovertamab ibrutinib vs ibrutinib in r/r mcl
-
1:52
sympatico: primary analysis results of ibrutinib plus venetoclax for patients with r/r mcl
-
1:30
final results of the aim study of ibrutinib and venetoclax in mantle cell lymphoma
-
1:35
long-term ibrutinib outcomes vs. prior regimens: pooled analysis in r/r mcl
-
6:28
cytoquest™ cr ctc enrichment - rbc lysis
-
1:05
cinematic rendering animation of an hepatobiliary tumor
-
5:00
diagnosing and treating al amyloidosis: a 2020 update from dr morie gertz
-
5:34
venetoclax added to ibrutinib in patients with cll with molecular resistance to btki treatment
-
0:26
acalabrutinib plus venetoclax and rituximab in the treatment of mcl
-
2:00
preliminary results of the aim trial of ibrutinib and venetoclax in mantle cell lymphoma
-
3:07
ibrutinib venetoclax in treatment-naïve wm: results from a phase ii trial
-
1:36
improve study update: safety and efficacy of venetoclax retreatment in r/r cll
-
3:27
venetoclax: an unmet need in r/r mantle cell lymphoma after btk inhibitors
-
5:54
updates from captivate: ibrutinib and venetoclax for cll
-
1:43
third interim analysis from vision: ibrutinib/venetoclax in r/r cll
-
1:51
the safety and efficacy of retreatment with venetoclax plus rituximab in r/r cll
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸